10 of the 10 current GLP-1 labels carry a warning on severe stomach problems. Wegovy's label says: "Use of Wegovy has been associated with gastrointestinal adverse reactions, sometimes severe."
Read from each manufacturer's FDA label on DailyMed. The newest revision saying anything on this is Aug 28, 2026.
Word for word
What each label says about severe stomach problems
Sentences from each label's warnings and side effect sections. Only cross-references are removed.
Wegovy · Warning: Severe Gastrointestinal Adverse Reactions
Use of Wegovy has been associated with gastrointestinal adverse reactions, sometimes severe.
In clinical trials for adults for weight reduction, severe gastrointestinal adverse reactions were reported more frequently among patients receiving Wegovy than placebo.
Severe gastrointestinal adverse reactions were reported in 4.1% and 0.9% of Wegovy injection and placebo-treated patients, respectively, and in 2% of Wegovy tablet-treated and 0% of placebo-treated patients, respectively.
Ozempic · Warning: Severe Gastrointestinal Adverse Reactions
Use of Ozempic has been associated with gastrointestinal adverse reactions, sometimes severe.
In Ozempic clinical trials, severe gastrointestinal adverse reactions were reported more frequently among patients receiving Ozempic (0.5 mg 0.4%, 1 mg 0.8%) than placebo (0%).
Severe gastrointestinal adverse reactions have also been reported postmarketing with GLP-1 receptor agonists.
Use of semaglutide tablets has been associated with gastrointestinal adverse reactions, sometimes severe.
In clinical trials, severe gastrointestinal adverse reactions were reported more frequently among patients who received semaglutide tablets (7 mg 0.6%, 14 mg 2%) than placebo (0.3%).
Severe gastrointestinal adverse reactions have also been reported postmarketing with GLP-1 receptor agonists.
Zepbound · Warning: Severe Gastrointestinal Adverse Reactions
Use of Zepbound has been associated with gastrointestinal adverse reactions, sometimes severe.
In a pool of two Zepbound clinical trials for weight reduction (Studies 1 and 2), severe gastrointestinal adverse reactions were reported more frequently among patients receiving Zepbound (5 mg 1.7%, 10 mg 2.5%, 15 mg 3.1%) than placebo (1%).
Similar rates of severe gastrointestinal adverse reactions were observed in Zepbound clinical trials for weight reduction and in Zepbound clinical trials for OSA.
Mounjaro · Warning: Severe Gastrointestinal Adverse Reactions
Use of Mounjaro has been associated with gastrointestinal adverse reactions, sometimes severe.
In the pool of placebo-controlled trials in adults, severe gastrointestinal adverse reactions occurred more frequently among patients receiving Mounjaro (5 mg 1.3%, 10 mg 0.4%, 15 mg 1.2%) than placebo (0.9%).
Severe gastrointestinal adverse reactions have also been reported postmarketing with GLP-1 receptor agonists.
Foundayo · Warning: Severe Gastrointestinal Reactions
Use of Foundayo has been associated with gastrointestinal adverse reactions, sometimes severe.
In clinical trials, severe gastrointestinal adverse reactions were reported more frequently among patients treated with orforglipron (approximately 3%) than patients who received placebo (1%).
Severe gastrointestinal adverse reactions have also been reported postmarketing with GLP-1 receptor agonists.
Trulicity · Warning: Severe Gastrointestinal Adverse Reactions
Use of Trulicity has been associated with gastrointestinal adverse reactions, sometimes severe.
In the pool of placebo-controlled trials, severe gastrointestinal adverse reactions were reported more frequently among patients receiving Trulicity (0.75 mg 2.2%, 1.5 mg 4.3%) than placebo (1.4%).
Severe gastrointestinal adverse reactions have also been reported postmarketing with GLP-1 receptor agonists.
Saxenda · Warning: Severe Gastrointestinal Adverse Reactions
Use of GLP-1 receptor agonists, including liraglutide, has been associated with gastrointestinal adverse reactions, sometimes severe.
In Saxenda clinical trials, severe gastrointestinal adverse reactions were reported more frequently among patients receiving Saxenda (4.8%) than placebo (1.4%).
Severe gastrointestinal adverse reactions have also been reported postmarketing with GLP-1 receptor agonists.
Victoza · Warning: Severe Gastrointestinal Adverse Reactions
Use of GLP-1 receptor agonists, including liraglutide, has been associated with gastrointestinal adverse reactions, sometimes severe.
In Victoza clinical trials, severe gastrointestinal adverse reactions were reported more frequently among patients receiving Victoza (1.2 mg 4.4%, 1.8 mg 4.2%) than placebo (1.1%).
Severe gastrointestinal adverse reactions have also been reported postmarketing with GLP-1 receptor agonists.
Counts of voluntary reports from patients and doctors. They cannot show that a medicine caused anything and cannot give a rate, and a brand used by more people draws more reports.
Gastroparesis and severe stomach problems on a GLP-1: common questions
Does Wegovy cause gastroparesis?
Its FDA label: Use of Wegovy has been associated with gastrointestinal adverse reactions, sometimes severe. In clinical trials for adults for weight reduction, severe gastrointestinal adverse reactions were reported more frequently among patients receiving Wegovy than placebo.
Does Ozempic cause gastroparesis?
Its FDA label: Use of Ozempic has been associated with gastrointestinal adverse reactions, sometimes severe. In Ozempic clinical trials, severe gastrointestinal adverse reactions were reported more frequently among patients receiving Ozempic (0.5 mg 0.4%, 1 mg 0.8%) than placebo (0%).
Does Rybelsus cause gastroparesis?
Its FDA label: Use of semaglutide tablets has been associated with gastrointestinal adverse reactions, sometimes severe. In clinical trials, severe gastrointestinal adverse reactions were reported more frequently among patients who received semaglutide tablets (7 mg 0.6%, 14 mg 2%) than placebo (0.3%).
Does Zepbound cause gastroparesis?
Its FDA label: Use of Zepbound has been associated with gastrointestinal adverse reactions, sometimes severe. In a pool of two Zepbound clinical trials for weight reduction (Studies 1 and 2), severe gastrointestinal adverse reactions were reported more frequently among patients receiving Zepbound (5 mg 1.7%, 10 mg 2.5%, 15 mg 3.1%) than placebo (1%).
Does Mounjaro cause gastroparesis?
Its FDA label: Use of Mounjaro has been associated with gastrointestinal adverse reactions, sometimes severe. In the pool of placebo-controlled trials in adults, severe gastrointestinal adverse reactions occurred more frequently among patients receiving Mounjaro (5 mg 1.3%, 10 mg 0.4%, 15 mg 1.2%) than placebo (0.9%).
Does Foundayo cause gastroparesis?
Its FDA label: Use of Foundayo has been associated with gastrointestinal adverse reactions, sometimes severe. In clinical trials, severe gastrointestinal adverse reactions were reported more frequently among patients treated with orforglipron (approximately 3%) than patients who received placebo (1%).
Does Trulicity cause gastroparesis?
Its FDA label: Use of Trulicity has been associated with gastrointestinal adverse reactions, sometimes severe. In the pool of placebo-controlled trials, severe gastrointestinal adverse reactions were reported more frequently among patients receiving Trulicity (0.75 mg 2.2%, 1.5 mg 4.3%) than placebo (1.4%).
Does Saxenda cause gastroparesis?
Its FDA label: Use of GLP-1 receptor agonists, including liraglutide, has been associated with gastrointestinal adverse reactions, sometimes severe. In Saxenda clinical trials, severe gastrointestinal adverse reactions were reported more frequently among patients receiving Saxenda (4.8%) than placebo (1.4%).
Does Victoza cause gastroparesis?
Its FDA label: Use of GLP-1 receptor agonists, including liraglutide, has been associated with gastrointestinal adverse reactions, sometimes severe. In Victoza clinical trials, severe gastrointestinal adverse reactions were reported more frequently among patients receiving Victoza (1.2 mg 4.4%, 1.8 mg 4.2%) than placebo (1.1%).
Trial rates describe groups, not what one person will feel. Talk to your clinician before starting, stopping or changing a medicine.
GLPcompare is an informational data platform, not a medical provider or pharmacy. Nothing here is medical advice, a diagnosis, or a recommendation to start, stop, or change any treatment. Data is aggregated from public sources and can be incomplete or out of date. Always confirm with a licensed clinician and the current FDA label.